The impact of artificial intelligence on retinal disease management: Vision Academy retinal expert consensus.

IF 3 2区医学 Q1 OPHTHALMOLOGY

Current Opinion in Ophthalmology Pub Date : 2023-09-01 DOI:10.1097/ICU.0000000000000980

Carla Danese, Aditya U Kale, Tariq Aslam, Jane Barratt, Yu-Bai Chou, Bora Eldem, Nicole Eter, Richard Gale, Jean-François Korobelnik, Igor Kozak, Paolo Lanzetta, Xiaorong Li, Xiaoxin Li, Anat Loewenstein, Paisan Ruamviboonsuk, Taiji Sakamoto, Daniel S W Ting, Peter van Wijngaarden, Sebastian M Waldstein, David Wong, Lihteh Wu, Miguel A Zapata, Javier Zarranz-Ventura

{"title":"The impact of artificial intelligence on retinal disease management: Vision Academy retinal expert consensus.","authors":"Carla Danese, Aditya U Kale, Tariq Aslam, Jane Barratt, Yu-Bai Chou, Bora Eldem, Nicole Eter, Richard Gale, Jean-François Korobelnik, Igor Kozak, Paolo Lanzetta, Xiaorong Li, Xiaoxin Li, Anat Loewenstein, Paisan Ruamviboonsuk, Taiji Sakamoto, Daniel S W Ting, Peter van Wijngaarden, Sebastian M Waldstein, David Wong, Lihteh Wu, Miguel A Zapata, Javier Zarranz-Ventura","doi":"10.1097/ICU.0000000000000980","DOIUrl":null,"url":null,"abstract":"Purpose of review: The aim of this review is to define the \"state-of-the-art\" in artificial intelligence (AI)-enabled devices that support the management of retinal conditions and to provide Vision Academy recommendations on the topic.Recent findings: Most of the AI models described in the literature have not been approved for disease management purposes by regulatory authorities. These new technologies are promising as they may be able to provide personalized treatments as well as a personalized risk score for various retinal diseases. However, several issues still need to be addressed, such as the lack of a common regulatory pathway and a lack of clarity regarding the applicability of AI-enabled medical devices in different populations.Summary: It is likely that current clinical practice will need to change following the application of AI-enabled medical devices. These devices are likely to have an impact on the management of retinal disease. However, a consensus needs to be reached to ensure they are safe and effective for the overall population.","PeriodicalId":50604,"journal":{"name":"Current Opinion in Ophthalmology","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399953/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/ICU.0000000000000980","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: The aim of this review is to define the "state-of-the-art" in artificial intelligence (AI)-enabled devices that support the management of retinal conditions and to provide Vision Academy recommendations on the topic.

Recent findings: Most of the AI models described in the literature have not been approved for disease management purposes by regulatory authorities. These new technologies are promising as they may be able to provide personalized treatments as well as a personalized risk score for various retinal diseases. However, several issues still need to be addressed, such as the lack of a common regulatory pathway and a lack of clarity regarding the applicability of AI-enabled medical devices in different populations.

Summary: It is likely that current clinical practice will need to change following the application of AI-enabled medical devices. These devices are likely to have an impact on the management of retinal disease. However, a consensus needs to be reached to ensure they are safe and effective for the overall population.

Abstract Image

查看原文本刊更多论文

人工智能对视网膜疾病管理的影响:视觉学会视网膜专家共识。

综述的目的:本综述的目的是定义支持视网膜疾病管理的人工智能(AI)启用设备的“最先进”技术，并就该主题提供视觉学会的建议。最近的发现:文献中描述的大多数人工智能模型尚未被监管机构批准用于疾病管理目的。这些新技术很有前景，因为它们可以为各种视网膜疾病提供个性化治疗和个性化风险评分。然而，仍有几个问题需要解决，例如缺乏共同的监管途径，以及人工智能医疗设备在不同人群中的适用性缺乏明确性。摘要:随着人工智能医疗设备的应用，目前的临床实践可能需要改变。这些设备可能对视网膜疾病的治疗产生影响。然而，需要达成共识，以确保它们对全体人口是安全和有效的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Ophthalmology 医学-眼科学

CiteScore

6.80

自引率

5.40%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Ophthalmology is an indispensable resource featuring key up-to-date and important advances in the field from around the world. With renowned guest editors for each section, every bimonthly issue of Current Opinion in Ophthalmology delivers a fresh insight into topics such as glaucoma, refractive surgery and corneal and external disorders. With ten sections in total, the journal provides a convenient and thorough review of the field and will be of interest to researchers, clinicians and other healthcare professionals alike.